Dyadic International Improves Monoclonal Antibody (mAb) Productivity Utilizing C1 Gene Expression Platform to Manufacture Bio...
June 18 2018 - 9:50AM
Results Highlighted in BioProcess
International and the Global Bioprocessing and Bioanalytics
Congress 2018
JUPITER, Fla., June 18, 2018 (GLOBE NEWSWIRE) --
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 gene expression platform to speed up the development
and production of biologic vaccines and drugs at flexible
commercial scales, discussed its improvements to productivity of
its mAb yield using the C1 platform in an article published by
BioProcess International and at the Global Bioprocessing
and Bioanalytics Congress 2018.
In the BioProcess International article
Dyadic CEO Mark Emalfarb discussed the company’s research,
development and commercial activities for the development and
manufacturing of human and animal vaccines, monoclonal antibodies
(mAbs), biosimilars and/or biobetters, and other therapeutic
proteins.
Between January 2018 and May 2018, Dyadic has
improved the productivity of mAb yield using the C1 platform from
1.34 to 2.46 grams per liter per day, an increase of 84 percent.
Dyadic reached 9 grams per liter of the target mAb in only 90 hours
with 50 percent of the total protein produced as the target mAb.
This was accompanied by a 67 percent decrease in media cost. These
improvements were conducted by one of Dyadic’s contract research
organizations. These results were presented by Dr. Ronen Tchelet,
Dyadic’s Vice President of Research & Development, at the
Global Bioprocessing and Bioanalytics Congress 2018 in Prague on
May 24-25. To view Dr. Tchelet’s presentation, please visit the
following link:
https://www.dyadic.com/wp-content/uploads/2018/01/C1-Technology-Bioprocessing-Prague-May-24-2018.pdf.
“Dyadic was able to achieve what we believe are
record results in a relatively short time by identifying low-cost
chemically defined media and applying proprietary optimization and
process development to demonstrate record levels of monoclonal
antibody productivity,” Mr. Emalfarb said. “We are continuing our
R&D efforts and working with partners to further develop our C1
gene expression platform to become the platform of choice for
manufacturing protein-based biologics because of speed of
development and low cost of goods. The first wave of biologics that
we hope to develop are non-glycosylated Fab proteins, followed by
glycoproteins, and we expect to update our stakeholders on the
timing of these milestones.”
To read the BioProcess International
article, please visit the following link:
http://www.bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/dyadic-developing-biosimilars-using-cho-challenging-expression-tech/.
The article at this link is provided for informational purposes
only. Dyadic is not responsible for the content of the linked
article.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila, named C1.
The C1 microorganism, which enables the development and large scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
scales. Dyadic is using the C1 technology and other technologies to
conduct research, development and commercial activities for the
development and manufacturing of human and animal vaccines,
monoclonal antibodies, biosimilars/biobetters, and other
therapeutic proteins. Dyadic pursues research and development
collaborations, licensing arrangements and other commercial
opportunities with its partners and collaborators to leverage the
value and benefits of these technologies in development and
manufacture of biopharmaceuticals. In particular, as the aging
population grows in developed and undeveloped countries, Dyadic
believes the C1 technology may help bring biologic drugs to market
faster, in greater volumes, at lower cost, and with new properties
to drug developers and manufacturers and, hopefully, improve access
and cost to patients and the healthcare system, but most
importantly save lives.
Please visit Dyadic’s website at
http://www.dyadic.com for additional information, including details
regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
http://www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements involve risks, uncertainties and other factors that
could cause Dyadic’s actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements and are cautioned not
to place undue reliance on such forward-looking statements. Dyadic
expressly disclaims any intent or obligation to update or revise
any forward-looking statements to reflect actual results, any
changes in expectations or any change in events. Factors that could
cause results to differ materially include, but are not limited to:
(1) general economic, political and market conditions; (2) our
ability to carry out and implement our biopharmaceutical research
and business plans and strategic initiatives; (3) our ability to
retain and attract employees, consultants, directors and advisors;
(4) our ability to implement and successfully carry out Dyadic’s
and third parties research and development efforts; (5) our ability
to obtain new license and research agreements; (6) our ability to
maintain our existing access to, and/or expand access to third
party contract research organizations in order to carry out our
research projects for ourselves and third parties; (7) competitive
pressures and reliance on key customers and collaborators; and (8)
other factors discussed in Dyadic’s publicly available filings,
including information set forth under the caption “Risk Factors” in
our December 31, 2017 Annual Report filed with the OTC
Markets on March 27, 2018, and our March 31, 2017 Quarterly
Report filed with the OTC Markets on May 10, 2018. New risks
and uncertainties arise from time to time, and it is impossible for
us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Accounting Officer
Phone: +1 (561) 743-8333
Email: prawson@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024